A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.

Second-line NSCLC is a $1.8bn write-off, and Gilead plans phase 3 in SCLC.

ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.

Jazz's somewhat low-key SCLC drug scores its biggest win yet.

The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.

Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.

The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.

Five years after AbbVie pulled the plug on rova-T, DLL3 comes under the spotlight again.